Table 4

Response by dose group (best overall response)

GA101 dose (mg)
50/100 (n = 3)100/200 (n = 3)200/400 (n = 3)400/800 (n = 3)800/1200 (n = 3)1200/1200 (n = 3)1600/1600/ 800 (n = 3)All (N = 21)
CR/CRu* 1  1 1 1  1 5 
PR†‡ 1 1 1 1    4 
SD    1 2 2  5 
PD  2 1   1 2 6 
Death 1       1 
GA101 dose (mg)
50/100 (n = 3)100/200 (n = 3)200/400 (n = 3)400/800 (n = 3)800/1200 (n = 3)1200/1200 (n = 3)1600/1600/ 800 (n = 3)All (N = 21)
CR/CRu* 1  1 1 1  1 5 
PR†‡ 1 1 1 1    4 
SD    1 2 2  5 
PD  2 1   1 2 6 
Death 1       1 

PD indicates progressive disease.

*

One patient with PR at the end of treatment later converted to CR.

†

One patient with PR after 4 cycles of treatment experienced disease progression before the end of treatment (8 cycles).

‡

One patient who was stable at the end of treatment later converted to PR.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal